De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Crohn Disease
Clinical Remission Observed With Risankizumab in Crohn Disease Trials
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
Prevalence of Adverse Pregnancy Outcomes Assessed With Biologics for IBD
The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
Biosimilar Hulio Gets FDA Approval
The Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Prescribing Patterns for Initiation of Ustekinumab in Crohn Disease
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. ORLANDO – Prescribing patterns…
Effects of Adalimumab, Infliximab in Biologic-Naive IBD Patients
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. ORLANDO – Treatment with…
Reasons for Certolizumab Use Examined in Patients With Crohn Disease
To better understand the real-world prescribing patterns of certolizumab, researchers collected data from a large multicenter gastroenterology private practice dating back to 2008.
Biosimilar BI 695501 Comparable to Reference Product in Crohn Disease
Biosimilar BI 695501 demonstrated non-inferior efficacy and similar safety profile compared with the reference product adalimumab in patients with active Crohn disease.
